Novo Nordisk has launched its coagulation factor IX (recombinant) glycoPEGylated drug Rebinyn in the US for the treatment of patients suffering from haemophilia B.

Known to affect around 5,000 of the population, haemophilia B is a serious, chronic, inherited bleeding disease characterised by low levels of clotting factor IX protein that leads to prolonged or spontaneous bleeding.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Rebinyn has been formulated as an extended half-life injectable medicine that can be used to treat and control bleeding in both adults and children.

According to data from Phase III clinical trials, a single dose of 40IU/kg Rebinyn in adults demonstrated capability to increase factor activity above baseline levels by 94% and maintain average factor levels of 17% one week after dosing.

“The introduction of Rebinyn energises us to build on our rich legacy of making innovative medicines available for people with rare bleeding disorders.”

The drug was also investigated in the paradigm clinical trial programme, where it treated 98% of patient bleeds following administration of one or two doses.

In a separate surgical clinical study, one Rebinyn preoperative dose was found to be sufficient to successfully control bleeding during surgery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Novo Nordisk Biopharmaceuticals corporate vice-president Pia D’ Urbano said: “The introduction of Rebinyn energises us to build on our rich legacy of making innovative medicines available for people with rare bleeding disorders.”

Earlier this month, the firm also released two new injections, Ozempic (semaglutide) and Fiasp (insulin aspart) for diabetes patients in the US.

All three of Novo Nordisk’s newly launched medications were approved by the US Food and Drug Administration (FDA) last year.